$8.09
4.79% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US00654J1079
Symbol
ADXN

Addex Therapeutics Ltd - ADR Stock price

$8.09
+0.04 0.50% 1M
-1.04 11.39% 6M
+0.37 4.79% YTD
+0.55 7.28% 1Y
-4.51 35.80% 3Y
-274.11 97.13% 5Y
-281.91 97.21% 10Y
-281.91 97.21% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.37 4.79%
ISIN
US00654J1079
Symbol
ADXN
Industry

Key metrics

Basic
Market capitalization
$10.2m
Enterprise Value
$7.5m
Net debt
positive
Cash
$2.8m
Shares outstanding
116.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
14.5 | 10.5
EV/Sales
10.7 | 7.7
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
90.6%
Return on Equity
72.9%
ROCE
-33.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$700.0k | $965.9k
EBITDA
$-2.6m | $-4.1m
EBIT
$-2.6m | $-4.2m
Net Income
$-7.2m | $-10.5m
Free Cash Flow
$-2.0m
Growth (TTM | estimate)
Revenue
-6.7% | 85.8%
EBITDA
56.8% | -17.3%
EBIT
58.2% | -19.9%
Net Income
-205.6% | -218.0%
Free Cash Flow
73.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-375.4% | -421.3%
EBIT
-375.4%
Net
-1,026.7% | -1,088.0%
Free Cash Flow
-283.7%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
0.9%
Employees
23
Rev per Employee
$20.0k
Show more

Is Addex Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

2x Hold
22%
7x Sell
78%

Analyst Opinions

9 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Hold
22%
Sell
78%

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.70 0.70
7% 7%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.47 2.47
37% 37%
353%
- Research and Development Expense 0.86 0.86
70% 70%
123%
-2.63 -2.63
57% 57%
-376%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -2.63 -2.63
58% 58%
-376%
Net Profit -7.20 -7.20
206% 206%
-1,029%

In millions USD.

Don't miss a Thing! We will send you all news about Addex Therapeutics Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Addex Therapeutics Ltd - ADR Stock News

Neutral
GlobeNewsWire
24 days ago
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C.
Neutral
Seeking Alpha
about one month ago
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
about one month ago
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a...
More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office Switzerland
CEO Tim Dyer
Employees 23
Founded 2002
Website www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today